The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are:
* Will bezisterim decrease movement symptoms of Parkinson's disease?
* What medical problems do participants have when taking bezisterim?
Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease.
Participants will
* have a physical examination that includes an electrocardiogram
* take drug or placebo twice daily for four months
* visit a clinical site or receive an at home visit seven times over the course of five months

Start Date26 Mar 2025

Sponsor / Collaborator

BioVie, Inc.

NCT06847191

/ Not yet recruitingPhase 2

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue.
Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID.
Participants will:
* Take NE3107 or a placebo twice daily for 84 days
* Visit the clinic 5 times for checkups and tests and have a follow up phone call

Start Date01 Mar 2025

Sponsor / Collaborator

BioVie, Inc.

NCT05970575

/ RecruitingPhase 2IIT

Open Label Phase IIa Study Evaluating the Safety and Efficacy of NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Traumatic Brain Injury and inflammatory and metabolic parameters.

Start Date21 Dec 2023

Sponsor / Collaborator

BioVie, Inc.

100 Clinical Results associated with Triolex

100 Translational Medicine associated with Triolex

100 Patents (Medical) associated with Triolex

Literatures (Medical) associated with Triolex

01 Mar 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Progress in the study of anti-Alzheimer's disease activity of pyrimidine-containing bioactive molecules

Review

Author: Zhang, Qi ; Zhang, Di ; Zhang, Lin-Lin ; Liu, Yu-Lin ; Chui, Rui-Hao ; Zhang, Qian ; Ma, Li-Ying ; Li, Bing-Qian

Pyrimidines are aromatic, heterocyclic organic compounds characterized by a six-membered ring that contains four carbon atoms and two nitrogen atoms. They have been reported to exhibit a variety of biological activities such as antifungal, antiviral, and anti-Parkinsonian effects. Recently, there has been an increased focus on their potential anti-Alzheimer's properties. Several pyrimidine-based drugs and their analogs are currently undergoing various phases of clinical trials, indicating pyrimidine as a promising chemical structure for drug development. Notably, modifications to the pyrimidine structure significantly influence their activity against Alzheimer's disease. For instance, the introduction of heteroatoms into the pyrimidine ring or alternations in the length of the linkage region have been shown to enhance therapeutic efficacy. This review provides a comprehensive overview of pyrimidine derivatives as potential therapeutics for Alzheimer's disease, with a focus on structure-activity relationship (SAR) studies, design strategies, and binding mechanisms. These insights could pave the way for the development of more effective anti-Alzheimer's medications.

26 Jul 2024·MEDICINE

A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias

Article

Author: Rindner, Elisabeth ; Ahlem, Clarence ; Jordan, Kaya ; Hofmeister, Kaitlyn ; Reading, Christopher ; Pourat, Bijan ; Mahdavi, Kennedy ; Becerra, Sergio ; Venkatraman, Victoria ; Palumbo, Joseph ; Haroon, Jonathan ; Goodenowe, Dayan ; Zielinski, Margaret ; Kuhn, Taylor ; Surya, Jean Rama ; Jordan, Sheldon ; Zhang, Jeffrey

Background::

Alzheimer’s disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD.

Methods::

In this phase 2, open-label study, 23 patients with mild cognitive impairment or mild dementia received 20-mg oral NE3107 twice daily for 3 months. Primary endpoints assessed changes from baseline in neurophysiological health and oxidative stress (glutathione level) using advanced neuroimaging analyses. Secondary endpoints evaluated changes from baseline in neuropsychological health using cognitive assessments, including the 11-item Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment, Clinical Dementia Rating, Quick Dementia Rating Scale, Alzheimer’s Disease Composite Score, and Global Rating of Change (GRC). Exploratory endpoints assessed changes from baseline in neuroinflammation biomarkers (tumor necrosis factor alpha, TNF-α) and AD (amyloid beta and phosphorylated tau [P-tau]).

Results::

NE3107 was associated with clinician-rated improvements in cerebral blood flow and functional connectivity within the brain. In patients with MMSE ≥ 20 (mild cognitive impairment to mild AD; n = 17), NE3107 was associated with directional, but statistically nonsignificant, changes in brain glutathione levels, along with statistically significant improvements in ADAS-Cog11 (P = .017), Clinical Dementia Rating (P = .042), Quick Dementia Rating Scale (P = .002), Alzheimer’s Disease Composite Score (P = .0094), and clinician-rated GRC (P < .001), as well as in cerebrospinal fluid P-tau levels (P = .034) and P-tau:amyloid beta 42 ratio (P = .04). Biomarker analyses also demonstrated directional, but statistically non-significant, changes in plasma TNF-α, consistent with the expected mechanism of NE3107. Importantly, we observed a statistically significant correlation (r = 0.59) between improvements in TNF-α levels and ADAS-Cog11 scores (P = .026) in patients with baseline MMSE ≥ 20.

Conclusion::

Our results indicate that in this study NE3107 was associated with what appear to be positive neurophysiological and neuropsychological findings, as well as evidence of improvement in biomarkers associated with neuroinflammation and AD in patients diagnosed with dementia. Our findings are consistent with previous preclinical and clinical observations and highlight a central role of neuroinflammation in AD pathogenesis.

16 Apr 2024·Cureus Journal of Medical Science

A Review of Recent Advances in the Management of Alzheimer’s Disease

Review

Author: Pinto, Alvaro ; Thangwaritorn, Skylynn ; Razdan, Vidushi ; Pemminati, Sudhakar ; Ghafary, Suliman ; Metchikoff, Elena ; Lee, Christopher ; Rivera, Dominic

Alzheimer's disease (AD) is the most common neurodegenerative condition and a form of dementia encountered in medical practice. Despite many proposed and attempted treatments, this disease remains a major puzzle in the public health systems worldwide. The initial part of this article provides an overview and illustration of the primary mechanisms responsible for neuronal damage in AD. Subsequently, it offers a critical evaluation of the most noteworthy studies on pharmacological therapy for AD and outlines recent advancements and novel approaches to managing this condition. Main properties, categorization, Food and Drug Administration (FDA) status, mechanisms of action, benefits, and common side effects of the classical and the most recently proposed pharmacological treatments for AD are described. The conventional pharmacological agents revised comprise cholinesterase inhibitors, monoclonal antibodies, and other therapies, such as memantine, valproic acid, and rosiglitazone. The innovative reviewed pharmacological agents comprise the monoclonal antibodies: donanemab, gantenerumab, solanezumab, bapineuzumab, crenezumab, and semorinemab. Nutritional supplements such as alpha-tocopherol (vitamin E) and caprylidene are also revised. Tau and amyloid-targeting treatments include methylthioninium moiety (MT), leuco-methylthioninium bis (LMTM), an oxidized form of MT, and tramiprosate, which inhibits the beta-amyloid (Aβ) monomer aggregation into toxic oligomers. Antidiabetic and anti-neuroinflammation drugs recently proposed for AD treatment are discussed. The antidiabetic drugs include NE3107, an anti-inflammatory and insulin sensitizer, and the diabetes mainstream drug metformin. The anti-neuroinflammatory AD therapies include the use of sodium oligomannate (GV-971), infusions with intravenous immunoglobulin aiming to decrease plasma levels of the constituents of Aβ plaques, and masitinib, a tyrosine kinase inhibitor that impacts mast and microglia cells. Additional anti-inflammatory agents being currently tested in phase-2 clinical trials, such as atomoxetine (selective norepinephrine reuptake inhibitor), losartan (angiotensin 2 receptor agonist), genistein (anti-inflammatory isoflavone neuroprotective agent), trans-resveratrol (polyphenol antioxidant plant estrogen), and benfotiamine (synthetic thiamine precursor), were reviewed. Lastly, drugs targeting Alzheimer's-associated symptoms, such as brexpiprazole (serotonin dopamine activity modulator) and suvorexant (orexin receptor antagonist), respectively, used for agitation and insomnia in AD patients, are reviewed. As experimental investigations and clinical research progress, there is a possibility that a combination of newly tested medications and traditional ones may emerge as a promising treatment option for AD in the future.

105

News (Medical) associated with Triolex

20 Nov 2024

·www.globenewswire.com

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with Long COVID. Details for the presentation are as follows: Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVIDPoster number: 28Presentation date: November 21, 2024Presenter: Penelope Markham, Ph.D, Senior Vice President and Program Lead, Long COVID, BioVie Inc. About Long COVIDLong COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more. Common symptoms include lingering loss of smell and taste, extreme fatigue, and “brain fog,” though persistent cardiovascular and respiratory problems, muscle weakness, and neurologic issues have also been documented. The Centers for Disease Control recently reported that 6.8% of adults in the United States (more than 17 million individuals) currently or previously have long COVID1 though a recent analysis using real world data estimates the prevalence could be as high as 22%2. The loss in quality of life and earnings and increased medical costs has an enormous economic impact estimated to be $3.7 trillion3. To date there are no non-pharmacological or pharmacological therapies proven effective for treatment of long COVID. Terms of the Department of Defense AwardThe work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, by a fully funded award in the amount of $13,137,150 through the Peer Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson’s disease) and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com. References 1Ford ND, Agedew A, Dalton AF, Singleton J, Perrine CG, Saydah S. Notes from the Field: Long COVID Prevalence Among Adults — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:135–136. DOI: http://dx.doi.org/10.15585/mmwr.mm7306a4. 2 Azhir A et al. “Precision Phenotyping for Curating Research Cohorts of Patients with Unexplained Post-Acute Sequelae of COVID-19” Med DOI: 10.1016/j.medj.2024.10.009, in press 3Cutler, David M. 2022 The economic costs of Long COVID: An update. long_covid_update_7-22.pdf (harvard.edu) Forward-Looking StatementsThis press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Bruce Mackle Managing Director, LifeSci Advisors, LLC bmackle@lifesciadvisors.com For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com

Phase 2Orphan DrugFast Track

12 Nov 2024

·www.pharmaceutical-technology.com

DMTs are major clinical research focus for Parkinson’s disease, analysis shows

The World Health Organisation estimated that over 8.5 million people had PD in 2019. Credit: LE Photo / Shutterstock. Pipeline treatments across the seven major markets (7MM: France, Germany, Italy, Spain, the UK, the US and Japan) reflect a growing research trend prioritising disease-modifying therapies (DMTs) and non-motor symptom therapies in the treatment of Parkinson’s disease, according to new research. The current therapeutic landscape for Parkinson’s is heavily genericised, exhibiting a notable lack of available neuroprotective treatments. However, Lorraine Palmer, pharmaceuticals analyst at GlobalData, says this is changing. “There are a total of 93 products in Phase I-III development within the 7MM for the treatment of Parkinson’s,” Palmer said. “66% of these are prospective neuroprotective agents or DMTs. These investigational agents target the key mechanisms that have been implicated in the pathophysiology of Parkinson’s, such as alpha-synuclein aggregation and neuroinflammation, with the goal of slowing disease progression.” GlobalData is Pharmaceutical Technology ’s parent company. DMTs look to be a particularly significant piece of the Parkinson’s puzzle, and key opinion leaders interviewed by GlobalData agreed on the need for further research focus, despite complications presented by the differing pathogenesis of Parkinson’s across patients. One of the neuroprotective and DMT agents in late-stage development is Annovis Bio’s Posiphen (buntanetap tartrate) . The drug is aimed at inhibiting alpha-synuclein, and it is currently in Phase III development in the US and five major European markets. Elsewhere, a Phase III trial in the US has been planned for BioVie’s Triolex (bezisterim) , which is an inhibitor of inflammatory mediators and is thought to offer neuroprotective potential. Palmer added: “26% of the pipeline DMTs in the pipeline target alpha-synuclein aggregation. This is a divisive mechanism of action, with some key opinion leaders holding high hopes and others expressing scepticism, highlighting the failure of Prothena and Roche’s prasinezumab to meet its primary endpoint in the Phase II PASADENA trial (NCT03100149) and safety concerns due to the role of alpha-synuclein in healthy functioning.” Alongside DMTs, treating non-motor symptoms is also becoming a key research focus, highlighted by analysis which shows that 3% of the pipeline is specifically targeting Parkinson’s disease dementia (experienced by up to 80% of people with Parkinson’s ) and Parkinson’s disease psychosis (experienced to some degree by between 20% and 40% of people with Parkinson’s ). Research development appears to be addressing a broader spectrum of Parkinson’s challenges, and there is interest in antiparkinsonian agents, dopamine agonists and treatments for Parkinson’s disease related dementia. It suggests that the industry is looking to improve both motor and non-motor symptoms, addressing the broader spectrum of challenges faced by Parkinson’s patients. Palmer concluded: “The distribution of the 93 pipeline agents in the 7MM underscores a strong emphasis on neuroprotective and disease-modifying treatments, demonstrating an industry-wide focus toward therapies that could potentially slow the progression of Parkinson’s.”

Phase 2Phase 3

29 Oct 2024

·www.globenewswire.com

BioVie Inc. Announces Closing of Registered Direct Offering

CARSON CITY, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share. The gross proceeds to the Company from the offering are $3,243,180, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. ThinkEquity acted as sole placement agent for the offering. The shares of common stock offered in the registered direct offering were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-274083), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 18, 2023 and declared effective on August 28, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson’s disease) and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com. Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Bruce Mackle Managing Director, LifeSci Advisors, LLC bmackle@lifesciadvisors.com For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com

Orphan DrugFast Track

100 Deals associated with Triolex

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05212

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	BioVie, Inc.	05 Aug 2021
Parkinson Disease	Phase 2	United States	BioVie, Inc.	26 Mar 2025
Post Acute COVID 19 Syndrome	Phase 2	United States	BioVie, Inc.	01 Mar 2025
Brain Injuries, Traumatic	Phase 2	United States	BioVie, Inc.	21 Dec 2023
Fatigue	Phase 2	United States	BioVie, Inc.	21 Dec 2023
Sleep	Phase 2	United States	BioVie, Inc.	21 Dec 2023
Multiple Myeloma	Phase 2	United States	NeurMedix, Inc.	10 Aug 2022
Prostatic Cancer	Phase 2	United States	NeurMedix, Inc.	10 Aug 2022
Cognitive Dysfunction	Phase 2	United States	BioVie, Inc.	19 Jan 2022
Rheumatoid Arthritis	Phase 2	United States	Harbor Therapeutics, Inc.	01 Jul 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05227820 (CTgov)	Phase 2	Alzheimer Disease \| Cognitive Dysfunction	23	NE3107	ixssxqvwqp = edjbwjujew jpbhvwxjjz (tmovnylxhq, kpbuynoeob - tfqjcsjpcq) View more	-	09 Jul 2024
NCT04669028 (GlobeNewswire) Manual	Phase 3	Alzheimer Disease	-	Bezisterim	kihuejfaxw(jjkehccziv) = mgfmagbktg cflfhirnzw (tfjzcbkhws ) View more	Positive	25 Apr 2024
NCT04669028 (GlobeNewswire) Manual	Phase 3	Alzheimer Disease	57	placebo	ehjghowmas(nzenqjskov) = lpbjjipmcb tbnrcwqbki (jpgniatkua ) View more	Positive	29 Nov 2023
				NE3107	ehjghowmas(nzenqjskov) = szjlwzryat tbnrcwqbki (jpgniatkua ) View more
NCT04669028 (NM101, Biospace) Manual	Phase 3	Alzheimer Disease Amyloid β 42 \| Amyloid β 40	322	NE3107 20 mg	uuxthfikcm(kfglpznjgz) = Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL. saqinxsokr (salzsqjdlr ) View more	Positive	25 Oct 2023
MDS 12023 \| MDS 22023 Manual	Phase 2	Parkinson Disease	39	NE3107+carbidopa/levodopa	pczwvorxtq(gscfzapflm) = All patients tolerated NE3107 well, and no drug-related adverse events were reported. eyhmafnmwj (lpzzbwturu ) View more	Positive	30 Aug 2023
				placebo+carbidopa/levodopa
NCT05083260 (NM201, NEWS) Manual	Phase 2	Alzheimer Disease \| Parkinson Disease	45	Carbidopa+Levodopa hydrate+HE 3286	gwljfvlnak(ctnjkkukgs) = nvfcamvwfh uzxieafsxo (givqtuiirr ) View more	Positive	05 Dec 2022
				Carbidopa+Levodopa hydrate+Placebo	eopijxxjod(ewuyrsynqr) = tseaqmanwo shnmvmwtkr (lvzicqbyku )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis